☆ 4.4 Meeting Abstract

A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL

Volume 93, Issue -, Pages 161-162

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.12588

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML

Mario Tiribelli, Roberto Latagliata, Massimo Breccia, Isabella Capodanno, Maria Cristina Miggiano, Francesco Cavazzini, Cristina Bucelli, Immacolata Attolico, Sabrina Leonetti Crescenzi, Sabina Russo, Mario Annunziata, Federica Sora, Massimiliano Bonifacio, Olga Mulas, Giuseppina Loglisci, Alessandro Maggi, Gianni Binotto, Elena Crisa, Anna Rita Scortechini, Anna Paola Leporace, Rosaria Sancetta, Pamela Murgano, Elisabetta Abruzzese, Fabio Stagno, Davide Rapezzi, Debora Luzi, Iolanda Vincelli, Monica Bocchia, Carmen Fava, Alessandra Malato, Monica Crugnola, Michele Pizzuti, Francesca Lunghi, Sara Galimberti, Matteo Dalmazzo, Renato Fanin, Emilia Scalzulli, Robin Foa, Alessandra Iurlo, Giuseppe Saglio, Giorgina Specchia

Summary: This study analyzed the use of frontline TKI therapy in Italian patients with CP-CML and found that 55% of patients chose imatinib as their first-line treatment, while second-generation TKIs were predominantly used in younger patients and those without comorbidities.

CANCER (2023)

Add to Collection

Article Oncology

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Kapil Saxena, Elias Jabbour, Ghayas Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan Kadia, Courtney D. DiNardo, Marina Konopleva, Jorge E. Cortes, Musa Yilmaz, Kelly Chien, Sherry Pierce, Hagop Kantarjian, Nicholas J. Short

Summary: This retrospective study of 104 consecutive patients with myeloid blast phase CML (CML-MBP) found that combination therapy with intensive chemotherapy (IC) + tyrosine kinase inhibitors (TKI) or hypomethylating agent (HMA) + TKI led to improved response rates, lower 5-year cumulative incidence of relapse, better 5-year event-free survival, and higher overall survival compared to TKI alone, particularly for patients who received a 2nd/3rd-generation TKI. Additionally, among patients treated with IC/HMA + TKI, those who received a 2nd/3rd generation TKI had superior event-free survival and overall survival compared to those who received imatinib-based therapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Hematology

Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

Elias Jabbour, Koji Sasaki, Fadi G. Haddad, Ghayas C. Issa, Jeffrey Skinner, Sara Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia-Manero, Koichi Takahashi, Gautam Borthakur, Naveen Pemmaraju, Sherry Pierce, Hagop Kantarjian

Summary: This study compared the outcomes of patients with CML-CP treated with low-dose and standard-dose dasatinib. The results showed that low-dose dasatinib is at least as effective as standard-dose dasatinib in treating CML-CP, with a better safety profile and drug exposure.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network

Giorgina Specchia, Patrizia Pregno, Massimo Breccia, Fausto Castagnetti, Chiara Monagheddu, Massimiliano Bonifacio, Mario Tiribelli, Fabio Stagno, Giovanni Caocci, Bruno Martino, Luigiana Luciano, Michele Pizzuti, Antonella Gozzini, Anna Rita Scortechini, Francesco Albano, Micaela Bergamaschi, Isabella Capodanno, Andrea Patriarca, Carmen Fava, Giovanna Rege-Cambrin, Federica Sora, Sara Galimberti, Monica Bocchia, Gianni Binotto, Giovanni Reddiconto, Paolo DiTonno, Alessandro Maggi, Grazia Sanpaolo, Maria Stella De Candia, Valentina Giai, Elisabetta Abruzzese, Maria Cristina Miggiano, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, Luciano Levato, Olga Mulas, Fabio Saccona, Gianantonio Rosti, Pellegrino Musto, Francesco Di Raimondo, Fabrizio Pane, Michele Baccarani, Giuseppe Saglio, Giovannino Ciccone

Summary: This study found that CML patients treated with imatinib had higher mortality rates, while those treated with 2nd generation TKIs had better survival rates. The ELTS score was associated with CML-related mortality, while age, CCI, ELTS score, and treatment with 2GTKIs were associated with an increased risk of non-CML related mortality. ELTS score showed better discriminant ability than Sokal score in all comparisons.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China

Fang Cheng, Guolin Yuan, Qiang Li, Zheng Cui, Weiming Li

Summary: This study confirmed the long-term efficacy and safety of imatinib for treating Chinese CML patients. Additionally, it demonstrated the feasibility of imatinib dose reduction and treatment-free remission attempts in patients with sustained stable deep molecular response after years of imatinib treatment in real-life settings.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Eda Nuhoglu Kantarci, Ece Tolgay, Ahmet Emre Eskazan

Summary: This editorial discusses the search for the best patient-based treatment option as well as evaluates a recent study by Tiribelli et al., published in Cancer.

CANCER (2023)

Add to Collection

Article Oncology

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML

Frederic Millot, Meinolf Suttorp, Stephanie Ragot, Guy Leverger, Jean-Hugues Dalle, Caroline Thomas, Nathalie Cheikh, Brigitte Nelken, Marilyne Poiree, Genevieve Plat, Birgitta Versluys, Birgitte Lausen, Marina Borisevich

Summary: The study evaluated the rate of children with childhood chronic myeloid leukemia who remained in molecular response after discontinuing imatinib following sustained deep molecular response (DMR). The findings showed fluctuating molecular free remission rates at different time points post-discontinuation, with no significant influencing factors identified.

CANCERS (2021)

Add to Collection

Article Oncology

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

Almudena Callejo, Sara Faouzi, Olivier Bouche, Francois Bertucci, Thomas Chevalier, Nicolas Isambert, Florence Duffaud, Olivier Collard, Nicolas Penel, Philippe Terrier, Olivier Mir, Jean Yves Blay, Axel Le Cesne

Summary: Retrospective analysis suggests that adjuvant imatinib 400 mg daily may benefit high-risk patients with advanced KIT exon 9-mutated GIST. Patients with advanced disease receiving imatinib 400 mg with dose escalation had a similar time to progression as those starting with 800 mg. In this setting, intra-patient dose escalation could be considered as an option.

TARGETED ONCOLOGY (2021)

Add to Collection

Article Infectious Diseases

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg ql2h) regimen

Romain Palich, Clotilde Allavena, Gilles Peytavin, Cathia Soulie, Roland Tubiana, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Aurore Durand, Minh-Patrick Le, Anne-Genevieve Marcelin, Yasmine Dudoit, Lambert Assoumou, Christine Katlama

Summary: The study aimed to evaluate the efficacy of switching patients from a twice-daily to a once-daily regimen of etravirine/raltegravir in maintaining viral suppression. The results showed a low rate of virological failure and a high treatment success rate at 48 weeks post-switch.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Tingting Lu, Jiangyan Cao, Fengming Zou, Xixiang Li, Aoli Wang, Wenliang Wang, Huamin Liang, Qingwang Liu, Chen Hu, Cheng Chen, Zhenquan Hu, Wenchao Wang, Lili Li, Jian Ge, Yang Shen, Tao Ren, Jing Liu, Ruixiang Xia, Qingsong Liu

Summary: CHMFL-48 is a novel type II kinase inhibitor that potently inhibits the wild-type BCR-ABL kinase and a panel of imatinib-resistant mutants. This drug shows strong inhibitory activity in a cellular context, blocking autophosphorylation of BCR-ABL kinase, affecting downstream signaling mediators, and inducing cell cycle progression blockade and apoptosis.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Review Oncology

What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?

Nancy Delgado, Anahi Torres

Summary: This review examines the relationship between chronic myeloid leukemia (CML) and COVID-19, including the risk factors, prognosis, and the role of tyrosine kinase inhibitors (TKIs). The findings suggest that CML patients in the chronic phase are not at a higher risk of infection by SARS-CoV-2 than the general population. TKIs may have a therapeutic effect against COVID-19, but further large-scale studies are needed to confirm this.

CURRENT ONCOLOGY REPORTS (2022)

Add to Collection

Article Hematology

Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings

Louis Nevejan, Veerle Labarque, Nancy Boeckx

Summary: This study confirmed that TKI significantly improved the prognosis of pediatric CML. However, drug compliance poses a considerable challenge.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study

Xuelin Dou, Fangyuan Zheng, Liqiang Zhang, Jie Jin, Yanli Zhang, Bingcheng Liu, Li Meng, Xiaofan Zhu, Zesheng Lu, Yueping Jia, Huilan Liu, Hai Lin, Li Zhou, Xielan Zhao, Wei Yang, Hui Sun, Sixuan Qian, Hongxia Ma, Xin Du, Qingxian Bai, Na Xu, Fanjun Meng, Zhilin Jia, Haixia Di, Leping Zhang, Qian Jiang

Summary: Compared to children, adolescents with CML-CP showed higher white blood cell counts, basophil percentages, and prevalence of splenomegaly. Both children and adolescents presented with more aggressive clinical features than adults, but achieved superior treatment responses in terms of complete cytogenetic response, major molecular response, and molecular response. Children had significantly longer failure-free survival compared to both adults and adolescents. Age was not associated with progression-free survival or overall survival, indicating that despite exhibiting more aggressive clinical features at diagnosis, children and adolescents had better treatment outcomes than adults.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?

Xiao-Shuai Zhang, Robert Peter Gale, Xiao-Jun Huang, Qian Jiang

Summary: The study found that the ELTS score was more accurate in predicting outcomes of chronic-phase chronic myeloid leukemia patients compared to the Sokal score, especially in those receiving 2nd-generation tyrosine-kinase inhibitor therapy. Patients identified as intermediate risk by the ELTS score may benefit more in achieving surrogate endpoints, particularly when a briefer interval to stopping TKI therapy is the therapy objective.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients

Esraa K. Al-Amleh, Ola M. Al-Sanabra, Khalid M. Alqaisi, Moath Alqaraleh, Jumana Al-Nahal, Lama Hamadneh, Mohammed Imad Malki, Jehad F. Alhmoud

Summary: This study compared the effects of single and combined treatment of IM and HU on hematological parameters and gene expression in CML patients. The findings suggest that the combined therapy is more effective in raising lymphocyte count and reducing the proportion of neutrophils compared to single medicines.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Hematology

Management of polycythemia vera: A survey of treatment patterns in Italy

Giuseppe Alberto Palumbo, Massimo Breccia, Claudia Barate, Massimiliano Bonifacio, Elena Maria Elli, Alessandra Iurlo, Novella Pugliese, Elena Rossi, Paola Guglielmelli, Francesca Palandri

Summary: Objectives Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder characterized by overproduction of red blood cells. Treatment patterns for PV patients in Italy vary greatly across different aspects. This survey highlights the need for more precise clinical guidance for routine care of PV patients.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon

Andrea Ghelli Luserna di Rora, Mouna Jandoubi, Giovanni Martinelli, Giorgia Simonetti

Summary: Uncontrolled proliferative signals and cell cycle dysregulation are important drivers of leukemia, and new compounds targeting cell cycle proteins and oncogenic mechanisms show promising therapeutic potential. The development of kinase inhibitors, microtubule-depolymerizing agents, P53-restoring agents, G-quadruplex-stabilizing molecules, and inhibitors of CDK2, CHK1, PI3K delta, STAT5, BRD4, and BRPF1 have shown effectiveness in inhibiting leukemia growth. Further investigation is needed to evaluate their toxicity, bio-availability, and efficacy in clinical settings.

MOLECULES (2023)

Add to Collection

Article Nutrition & Dietetics

The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling

Sara Salucci, Alberto Bavelloni, Anna Bartoletti Stella, Francesco Fabbri, Ivan Vannini, Manuela Piazzi, Karyna Volkava, Katia Scotlandi, Giovanni Martinelli, Irene Faenza, William Blalock

Summary: Approximately 7% of childhood cancers and 1% of adult cancers are soft tissue sarcomas, with rhabdomyosarcoma being the most common subtype. Despite current therapeutic protocols, survival rates for RMS have not improved significantly in the past decade. Curcumin, derived from the Curcuma longa plant, has low toxicity and has shown anti-tumorigenic effects in vitro. This study evaluated curcumin's activity in RMS cell lines and identified the major pathways affected by curcumin's anti-tumorigenic effects. Curcumin treatment resulted in cell cycle arrest, inhibited migration and colony formation, and induced apoptosis. Proteome profiler analysis revealed that curcumin primarily influenced signaling through AKT-mTOR, STAT, AMPK, and p53 pathways in a subtype-specific manner. Combinational therapeutic targeting of these pathways may be the best option for RMS treatment.

NUTRIENTS (2023)

Add to Collection

Article Orthopedics

Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty

Davide Golinelli, Alberto Grassi, Francesco Sanmarchi, Dario Tedesco, Francesco Esposito, Simona Rosa, Paola Rucci, Marilina Amabile, Monica Cosentino, Barbara Bordini, Maria Pia Fantini, Stefano Zaffagnini

Summary: This study aimed to explore the trajectories of quality of life and joint functioning in patients undergoing elective total knee arthroplasty (TKA), as well as the associated demographic and clinical features. The results showed that most patients reported improved quality of life and joint functioning at 6 months after surgery, with stable outcomes thereafter. However, there were subgroups with more varied trajectories. Female patients had worse perceived quality of life and joint function before surgery but showed more rapid improvement after surgery. Patients with an ASA score greater than 3 had worse functional recovery after TKA.

BMC MUSCULOSKELETAL DISORDERS (2023)

Add to Collection

Article Oncology

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata M. M. Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michele Cavo, Massimiliano Bonifacio, Giuseppe A. A. Palumbo

Summary: This study explored the prognostic factors of cytopenic myelofibrosis (MF) and found that high molecular risk mutations, intermediate 2/high Dynamic International Prognostic Score System, and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model were associated with cytopenic MF. Patients with cytopenia received lower doses of ruxolitinib and had worse treatment outcomes, suggesting the need for alternative therapeutic strategies.

CANCER (2023)

Add to Collection

Article Oncology

The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy

Yasemin Karacan, Hicran Yildiz, Turkkan Evrensel, Ibrahim Celalettin Haznedaroglu

Summary: This study found that Ankaferd hemostat can effectively prevent oral mucositis in colorectal cancer patients undergoing chemotherapy. Compared to the sodium bicarbonate group, the Ankaferd hemostat group showed significant differences in mucositis grades on the 7th and 15th day.

SUPPORTIVE CARE IN CANCER (2023)

Add to Collection

Letter Oncology

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D'Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, Massimo Breccia

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Genetics & Heredity

Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study

Deborah F. Nacer, Johan Vallon-Christersson, Nicklas Nordborg, Hans Ehrencrona, Anders Kvist, Ake Borg, Johan Staaf

Summary: The study found that breast tumors in patients screened for PGVs showed more aggressive characteristics, especially in the case of triple-negative breast cancer (TNBC). However, the ability to improve screening accuracy using current patient and tumor characteristics remains questionable and further research is needed.

GENOME MEDICINE (2023)

Add to Collection

Article Genetics & Heredity

Detection of a Novel MSI2-C17orf64 Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report

Anna Ferrari, Roberto Fiocca, Elena Bonora, Chiara Domizio, Eugenio Fonzi, Davide Angeli, Gian Domenico Raulli, Sandro Mattioli, Giovanni Martinelli, Chiara Molinari

Summary: This study conducted genomic analysis on a neoadjuvant chemotherapy-resistant gastroesophageal tumor and identified a novel gene fusion, MSI2-C17orf64, that has never been reported before. This finding highlights the potential of MSI2 as a therapeutic target.

GENES (2023)

Add to Collection

Article Oncology

Correlations between Molecular Alterations, Histopathological Characteristics, and Poor Prognosis in Esophageal Adenocarcinoma

Arianna Orsini, Luca Mastracci, Isotta Bozzarelli, Anna Ferrari, Federica Isidori, Roberto Fiocca, Marialuisa Lugaresi, Antonietta D'Errico, Deborah Malvi, Erica Cataldi-Stagetti, Paola Spaggiari, Anna Tomezzoli, Luca Albarello, Ari Ristimaki, Luca Bottiglieri, Kausilia K. Krishnadath, Riccardo Rosati, Uberto Fumagalli Romario, Giovanni De Manzoni, Jari Rasanen, Giovanni Martinelli, Sandro Mattioli, Elena Bonora

Summary: Esophageal adenocarcinoma (EAC) is a severe malignancy with increasing incidence, poorly understood pathogenesis, and low survival rates. TP53 gene alterations, especially missense mutations, negatively affect cancer-specific survival in EAC. HNF1alpha gene disruption is associated with other gene alterations and is identified as a new EAC-mutated gene.

CANCERS (2023)

Add to Collection

Review Oncology

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi

Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.

CANCERS (2023)

Add to Collection

Article Oncology

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W. Zuurman, Rajendra Sarkar, Vikas Gupta

Summary: Bone marrow fibrosis (BMF) is a negative prognostic factor for myelofibrosis (MF). The JUMP trial investigated the safety and efficacy of the JAK1/JAK2 inhibitor ruxolitinib in symptomatic MF patients. This post hoc analysis found that patients with low-grade fibrosis (LGF) had better response rates and survival estimates compared to patients with high-grade fibrosis (HGF). Early initiation of ruxolitinib therapy was associated with increased response rates in all patients.

CANCERS (2023)

Add to Collection

Article Oncology

Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer

Anna Ofverholm, Therese Toerngren, Anna Rosen, Brita Arver, Zakaria Einbeigi, Karin Haraldsson, Anne Kinhult Stahlbom, Ekaterina Kuchinskaya, Annika Lindblom, Beatrice Melin, Ylva Paulsson-Karlsson, Marie Stenmark-Askmalm, Emma Tham, Anna von Wachenfeldt, Anders Kvist, Ake Borg, Hans Ehrencrona

Summary: This study assessed the genetic variation in a large cohort of women with suspected HBOC and found that extending clinical genetic screening from BRCA1 and BRCA2 to 13 established cancer predisposition genes almost doubles the diagnostic yield. This has implications for genetic counseling and clinical guidelines.

BMC CANCER (2023)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Public attitudes challenge clinical practice on genetic risk disclosure in favour of healthcare-provided direct dissemination to relatives

Anna Rosen, Mateja Krajc, Hans Ehrencrona, Svetlana Bajalica-Lagercrantz

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Add to Collection

Review Hematology

How I Manage Chronic Lymphocytic Leukemia

Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli, Alessandra Ferrajoli

Summary: Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. Targeted therapies, including BTK inhibitors and BCL2 inhibitors, have become the standard of care for CLL treatment in the United States and Europe. These therapies have a good safety profile overall, but can also have unique toxicities.

HEMATOLOGY REPORTS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.